David W Sirbasku

Author:

David A. Sirbasku

ISBN #:

0121820467

Author:

David A. Sirbasku

ISBN #:

0121820475

Author:

David A. Sirbasku

ISBN #:

0471833223

Author:

David A. Sirbasku

ISBN #:

0845138006

Author:

David A. Sirbasku

ISBN #:

0845138014

Author:

David A. Sirbasku

ISBN #:

0845138022

Author:

David A. Sirbasku

ISBN #:

0845138030

US Patent:

8563249, Oct 22, 2013

Filed:

May 20, 2011

Appl. No.:

13/112444

Inventors:

David A. Sirbasku - Flower Mound TX, US

Assignee:

Signe BioPharma Inc. - Irving TX

International Classification:

C12Q 1/68
G01N 33/567
G01N 33/574

US Classification:

435 611, 435 614, 435 721, 435 723, 436 63, 436 64, 436503, 436813

Abstract:

Compositions and methods that use the body's natural secretory immune system in a new way against steroid hormone responsive tumors of the breast and prostate, as well as other glandular/mucus epithelial tissues such as colon, ovary, endometrium, kidney, bladder, stomach, pancreas and secretory pituitary gland are provided. Also provided are new ways of identifying carcinogenic, or potentially carcinogenic, bacteria in a tissue or body fluid to provide better anti-cancer therapies and preventatives than have been available previously.

US Patent:

20110086800, Apr 14, 2011

Filed:

Nov 30, 2010

Appl. No.:

12/956503

Inventors:

David A. Sirbasku - Irving TX, US

International Classification:

A61K 38/22
A61K 31/138
A61K 31/437
A61K 31/429
A61K 31/566
A61P 35/00

US Classification:

514 97, 514651, 514648, 514293, 514368, 514171

Abstract:

A method to aid in identifying a familial or sporadic pattern of risk in at least one individual for developing cancer of a mucosal epithelial tissue, the method comprising screening said at least one individual for heterozygosity or homozygosity for a mutation in a gene coding for a Poly-Ig (Fc) receptor or a Poly-Ig-like (Fc) receptor capable of mediating inhibition of cancer cell growth by an immunoglobulin inhibitor. A method of treating an individual so identified includes enhancing the amount of immunoglobulin inhibitor contacting a mucosal epithelial tissue of said individual, and, especially in individuals homozygous for the defective receptor, may also include prophylactic surgery. Other methods include implementation of a risk reduction or prevention program in individuals identified as being at risk.

US Patent:

20120034206, Feb 9, 2012

Filed:

Oct 14, 2011

Appl. No.:

13/273382

Inventors:

David Sirbasku - Irving TX, US

Assignee:

Signe Biopharma Inc. - Irving TX

International Classification:

A61K 39/108
A61K 39/395
A61P 35/00
A61K 39/00

US Classification:

4241301, 4241841, 4242571

Abstract:

A method of treating breast cancer that is at least partially ERis disclosed. The method comprises administering at a tumor site in a mammalian subject a pharmaceutically acceptable form of Fe(II) or Fe(III) in a suitable carrier. A four-part program aimed at eradicating breast cancer includes (a) local treatment and prevention of spread from a contained breast site, preferably using local administration of a ferric iron composition, (b) treatment of disseminated (metastatic) breast cancer, (c) reduction in the risk of developing breast cancer, preferably by enhancing dimeric/polymeric IgA and polymeric IgM inhibition of estrogen responsive cell growth, and (d) protection against cancer causing agents.

US Patent:

20120115161, May 10, 2012

Filed:

May 20, 2011

Appl. No.:

13/112391

Inventors:

David A. Sirbasku - Flower Mound TX, US

International Classification:

G01N 33/566
C12Q 1/02
C12N 5/09

US Classification:

435 71, 435408, 435 29

Abstract:

Serum-containing and serum-free immunoglobulin inhibitors of steroid hormone responsive cancer cell growth are disclosed, along with their methods of production. Also disclosed are defined cell culture media, assay protocols, and model systems using the inhibitors for demonstrating steroid hormone growth effects of natural and synthetic substances, and other cell culture applications. The disclosed compositions and methods employing the immunoglobulin inhibitors are also useful as reagents in research, and for the diagnosis, treatment and prevention of mucus epithelial cancers.